SanBio Company Limited (4592.T) JPX
1,272.00
-20(-1.55%)
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
1,272.00
-20(-1.55%)
Currency In JPY
Sector
Healthcare
Industry
Biotechnology
Employees
29
First IPO Date
April 08, 2015
| Name | Title | Pay | Year Born |
| Keita Mori | Co-Founder, President, Executive Officer, Chief Executive Officer & Representative Director | 0 | 1967 |
| Kazumi Sawaguchi | Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan | 0 | N/A |
| Dai Chida | Senior Scientific Advisor | 0 | N/A |
| Naoki Tsukahara | Senior Corporate Officer | 0 | N/A |
| Shinya Hirata | Corporate Officer & Head of Research and Development | 0 | N/A |
| Soyoku Nobeyama | Corporate Officer, Head of Japan Regulatory Affairs & Quality Compliance Japan | 0 | N/A |
| Tetsuya Isono | Corporate Officer & Head of Production | 0 | N/A |
| Toru Kawanishi | Co-Founder & Executive Chairman | 0 | 1967 |
| Yoshihiro Kakutani | Corporate Officer of Management Administration | 0 | N/A |
| Munetaka Nobeyama | Executive Officer, Head of Reliability Assurance & Regulatory Affairs Division | 0 | N/A |
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.